Quick Answer
HERON THERAPEUTICS, INC. /DE/ reported Research And Development Expense of $12.43 million for the year ending 2025.
- HERON THERAPEUTICS, INC. /DE/ showed a decrease of -25.5% in Research And Development Expense from 2024 to 2025.
- This data is from HERON THERAPEUTICS, INC. /DE/'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: $8.54 million | Q1 2014: $11.63 million | Q2 2014: $14.28 million | Q3 2014: $14.73 million | Q4 2014: $14.20 million | Q1 2015: $14.50 million | Q2 2015: $16.18 million | Q3 2015: $14.24 million | Q4 2015: $16.26 million | Q1 2016: $16.09 million | Q2 2016: $27.29 million | Q3 2016: $30.24 million | Q4 2016: $29.51 million | Q1 2017: $33.38 million | Q2 2017: $28.60 million | Q3 2017: $28.84 million | Q4 2017: $47.76 million | Q1 2018: $39.56 million | Q2 2018: $30.16 million | Q3 2018: $30.42 million | Q4 2018: $39.89 million | Q1 2019: $42.97 million | Q2 2019: $41.43 million | Q3 2019: $34.71 million | Q4 2019: $48.28 million | Q1 2020: $36.89 million | Q2 2020: $44.00 million | Q3 2020: $49.18 million | Q4 2020: $44.45 million | Q1 2021: $38.12 million | Q2 2021: $35.23 million | Q3 2021: $28.60 million | Q1 2022: $42.07 million | Q2 2022: $28.83 million | Q3 2022: $25.55 million | Q1 2023: $8.84 million | Q2 2023: $13.21 million | Q3 2023: $9.29 million | Q1 2024: $4.61 million | Q2 2024: $4.43 million | Q3 2024: $4.47 million | Q1 2025: $2.28 million | Q2 2025: $2.93 million | Q3 2025: $3.47 million.
- Over the full 17 years of available data (2009 to 2025), HERON THERAPEUTICS, INC. /DE/'s Research And Development Expense has grown by 59.4%.
- Historical annual values: Fiscal year 2025: $12.43 million | Fiscal year 2024: $16.68 million | Fiscal year 2023: $39.13 million | Fiscal year 2022: $82.70 million | Fiscal year 2021: $130.82 million | Fiscal year 2020: $174.53 million | Fiscal year 2019: $167.38 million | Fiscal year 2018: $140.03 million | Fiscal year 2017: $138.58 million | Fiscal year 2016: $103.13 million | Fiscal year 2015: $61.18 million | Fiscal year 2014: $54.83 million | Fiscal year 2013: $32.52 million | Fiscal year 2012: $15.17 million | Fiscal year 2011: $8.21 million | Fiscal year 2010: $7.26 million | Fiscal year 2009: $7.80 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: